Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Oct;26(10):1224-1228.
doi: 10.1111/jvh.13146. Epub 2019 Jun 20.

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

Sophie Willemse  1   2 , Colette Smit  2   3 , Philippe Sogni  4   5   6 , Mario Sarcletti  7   8 , Caterina Uberti-Foppa  9 , Linda Wittkop  6   10   11 , Dorthe Raben  12 , Antonella D'Arminio Monforte  13 , Francois Dabis  6   10   11 , Marc Van Der Valk  2   14 ; Hepatocellular Carcinoma Screening Project Working Group for the Collaboration of Observational HIV on behalf of Epidemiological Research Europe (COHERE) In EuroCoord
Collaborators, Affiliations
Observational Study

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

Sophie Willemse et al. J Viral Hepat. 2019 Oct.
No abstract available

Keywords: cancer screening; chronic viral hepatitis; co-infection; guideline adherence; hepatocellular carcinoma; hepatocellular carcinoma screening; human immunodeficiency virus; liver cirrhosis.

PubMed Disclaimer

Conflict of interest statement

CS, PS, MS, CUF and FD have no conflicts of interest; AdAM has received grants from Gilead and MSD Advisory boards from Gilead, Janssen, BMS, MSD and ViiV; LW reports personal fees from Janssen and Gilead (lectures on methodological issues in clinical research – past) outside the submitted work; SW has received consultancy fees from Abbvie, BMS, Gilead, Janssen, MSD, Roche, and research support from AbbVie, Gilead, Janssen, MSD, Roche; MvV has received consultancy fees from Abbvie, BMS, Gilead, Johnson & Johnson, MSD, Viiv and research support from Gilead, Johnson & Johnson, MSD and Viiv.

Figures

Figure 1
Figure 1
Absolute numbers and percentages of compliance with HCC screening guidelines ≤6 mo per calendar year. *6 mo is defined as a maximum interval of 6.5 mo between ultrasounds (a “grace period” of 2 wk)
See this image and copyright information in PMC

References

    1. Gjærde LI, Shepherd L, Jablonowska E, et al. Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C Virus‐coinfected individuals from 2001 to 2014: a Multicohort Study. Clin Infect Dis. 2016;63:821‐829. - PMC - PubMed
    1. Gaglio PJ, Sterling R, Daniels E, Tedaldi E,Terry Beirn Community Programs for Clinical Research on AIDS Hepatitis Working Group . Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy. Clin Infect Dis. 2007;45:618‐623. - PubMed
    1. Tran SA, Le AN, Zhao C, et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real‐life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018;5:e000192. - PMC - PubMed
    1. Wang C, Chen V, Vu V, et al. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine. 2016;95:e4744. - PMC - PubMed
    1. Wong CR, Garcia RT, Trinh HN, et al. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54:2712‐2721. - PubMed

Publication types